AVR-001 / Jiangsu Hansoh Pharma, Avere Therapeutics - LARVOL DELTA

A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy (The Manila Times) - "The Agreement brings together Avere’s differentiated oral IL-23 program with NextCure’s public market infrastructure to accelerate development of AVR-001. Upon completion of the transaction, which is expected to occur in the second half of 2026...The financing includes $251 million of convertible notes (and interest thereon) that will be exchanged for common stock concurrently with the closing of the merger. The private placement is expected to fully fund company operations through the readout of a global Phase 2b trial in psoriasis, commencement of a Phase 3 trial in psoriasis, and commencement of a Phase 2b trial in ulcerative colitis...A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028. A Phase 2b psoriasis study in China conducted by Hansoh is also expected to read out in 2027."

IND • M&A • New P2b trial • New P3 trial • P2b data • Immunology • Plaque Psoriasis • Ulcerative Colitis

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HS-20118 in healthy adults and psoriasis patients (SID 2026) - P1 | "There were no notable PK/PD differences between CN and NZ populations. HS-20118 demonstrated favorable safety, PK, PD profiles, and a similar efficacy to IL-23 monoclonal antibodies in psoriasis, supporting further development as a long-acting, oral therapy for immune-mediated diseases."

Clinical • PK/PD data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IFNG • IL17A • IL23A

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 (clinicaltrials.gov) - P1 | N=142 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis